The Allergan Campaign
A Hostile Bid in Partnership with Valeant
The unprecedented Allergan campaign, in which Pershing Square accumulated a toehold stake and partnered with Valeant to force a takeover of the Botox maker. The presentation argues that Allergan's standalone plan destroyed value relative to a Valeant combination, and that shareholders deserved the right to decide. The structure — activist as deal catalyst rather than bidder — broke new legal ground, though the partner chosen would later become the defining regret of Ackman's career.
“Valeant is a specialty pharmaceutical company that fits our investment criteria. Durable products/brands. Predictable financial results. Superior long-term growth in free cash flow per share. Culture of cost discipline and operational excellence. Shareholder-friendly capital allocation.”
Summary
"The Allergan Campaign" is the 110-slide presentation Pershing Square filed with the SEC in April 2014 as part of its joint bid with Valeant Pharmaceuticals for Allergan, the maker of Botox. The deck is both a takeover document and a manifesto for the golden-era Ackman: a concentrated, research-intensive activist using public disclosure as a weapon, a toehold stake as a catalyst, and a partner-CEO as the operator. Pershing Square had accumulated a 9.7% economic interest in Allergan through a rapid accumulation program, then proposed that shareholders be allowed to choose between Allergan's standalone plan and a Valeant combination. The presentation's central claim is not merely that Valeant's stock is cheap, but that the merged "Val-gan" would combine durable cash flows, a lower-cost operating model, and a disciplined acquisition platform in a way no traditional pharmaceutical company could replicate. The document therefore sits at the intersection of Ackman's activist premium, his admiration for outsider CEOs, and his emerging fascination with platform value — all before Valeant itself became the defining catastrophe of his career.
On Valeant as the first pharmaceutical company to fit Pershing Square's criteria:
"Valeant is a specialty pharmaceutical company that fits our investment criteria. Durable products/brands. Predictable financial results. Superior long-term growth in free cash flow per share. Culture of cost discipline and operational excellence. Shareholder-friendly capital allocation."
— The Allergan Campaign, Pershing Square Public Presentation, 2014
On why a traditional pharmaceutical company does not fit those same criteria:
"The traditional pharmaceutical company s products are not durable, and growth is not predictable."
— The Allergan Campaign, Pershing Square Public Presentation, 2014
On Valeant's claim to durable, non-patent-cliff revenue:
"Durable healthcare products are more comparable to high-margin consumer products than to traditional, patented pharma products."
— The Allergan Campaign, Pershing Square Public Presentation, 2014
On the acquisition machine that underwrote the platform thesis:
"Management has completed 100+ acquisitions and licenses, investing $19bn+ since 2008. Acquisitions have been highly accretive. Collectively, since 2008, Valeant has earned a >20% unlevered return (before tax efficiencies) on its acquisitions."
— The Allergan Campaign, Pershing Square Public Presentation, 2014
On the rapid accumulation program that created the activist toehold:
"Allergan s unaffected share price is $116.63, the closing price on April 10, the day before Pershing Square began its rapid accumulation program."
— The Allergan Campaign, Pershing Square Public Presentation, 2014
On the proposed economics and Pershing Square's own election:
"Allergan shareholders will own ~43% of the pro-forma company. Exchange ratio: 0.83 Valeant shares for every 1 Allergan share. Pershing Square Will Elect To Receive 100% Stock."
— The Allergan Campaign, Pershing Square Public Presentation, 2014
On the accounting framework used to justify Valeant's valuation:
"We believe GAAP accounting does a poor job tracking the economic performance of platform businesses like Valeant. To evaluate Valeant s business performance, we believe one first needs to translate GAAP earnings into economic earnings."
— The Allergan Campaign, Pershing Square Public Presentation, 2014
On the margin of safety embedded in the offer:
"Val-gan would need to trade at only 7.4x 2014 Pro-Forma Cash EPS1 in order for the Transaction value to exceed Allergan’s unaffected price"
— The Allergan Campaign, Pershing Square Public Presentation, 2014
On the outsider archetype Ackman saw in Mike Pearson:
"Mike Pearson is an Outsider CEO"
— The Allergan Campaign, Pershing Square Public Presentation, 2014
On the philosophical justification for doing what the market disliked:
"It is impossible to produce superior performance unless you do something different."
— The Allergan Campaign, Pershing Square Public Presentation, 2014
Key Themes
- The Activist Premium — Pershing Square did not launch a hostile tender itself; it built a toehold, partnered Valeant, and used public disclosure to force Allergan's board to put the combination to a shareholder vote
- The Right CEO — the deck frames Valeant's Mike Pearson as an "Outsider CEO" in the Thorndike mold, the capital-allocation-driven operator who could apply Valeant's cost discipline to Allergan's durable franchises
- Capital Allocation Discipline — the thesis rests on Valeant's history of accretive acquisitions, aggressive buybacks, and a refusal to fund high-risk discovery R&D
- Concentration as Risk Mitigation — the position was enormous relative to the fund, reflecting Ackman's belief that deep conviction in a well-understood catalyst is safer than diversification
- The Wide Gap: Price vs. Intrinsic Value — the presentation argues the market is valuing Allergan as a standalone 0% grower while ignoring the value creation available in a Valeant combination
- Avoiding Extrinsic Risks — the deck explicitly rejects traditional pharma's patent-cliff and political-pricing risks, though the partner it chose would soon become the largest extrinsic risk Ackman ever took
- J. Michael Pearson — the cautionary CEO at the center of the campaign; the man Ackman defended as an outsider would become the accelerant of Valeant's collapse
Context & Significance
This is Act II, the golden era, operating at maximum scale and self-confidence. The mindset behind the Allergan campaign is that the activist can be a deal catalyst rather than merely a gadfly: by combining a large toehold, a credible operating partner, and a public valuation argument, Pershing Square believed it could unlock value that Allergan's incumbent management would not pursue on its own. The deck is notable for what it assumes as much as for what it argues — that Valeant's acquisition platform is a sustainable competitive advantage, that its cash-net-income adjustments faithfully represent economic reality, and that a CEO who looks like an Outsider is therefore the right CEO.
The honest retrospective is that the logic was internally coherent but catastrophically partner-dependent. The Valeant model did generate enormous shareholder returns for six years; what the deck did not price was the fragility of that model once political scrutiny, acquisition math, and specialty-pharmacy accounting converged. Allergan ultimately escaped the bid through a white-knight sale to Actavis, and Pershing Square made money on the Allergan position — but the Valeant equity that Ackman elected to receive became the core of a roughly $4 billion loss. Read in 2014, the presentation is a crisp case for platform value and outsider management; read afterward, it is the document in which Ackman's golden-era confidence mistook a levered, price-raising pharmaceutical rollup for a durable, Buffett-quality franchise. The lesson that would eventually enter the Eight Commandments is visible here only in negative space: the right CEO cannot fix a business whose economics depend on forces outside management's control.